USD 1.94
(-11.82%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | -100.0% |
2020 | 431.8 Thousand USD | 4145.0% |
2019 | 10.17 Thousand USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2021 Q1 | - USD | -100.0% |
2021 FY | - USD | -100.0% |
2021 Q4 | - USD | -100.0% |
2021 Q3 | 13.88 Thousand USD | 0.0% |
2020 FY | 431.8 Thousand USD | 4145.0% |
2020 Q4 | 431.8 Thousand USD | 0.0% |
2019 FY | 10.17 Thousand USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AIM ImmunoTech Inc. | 495 Thousand USD | 100.0% |
Ampio Pharmaceuticals, Inc. | - USD | NaN% |
Armata Pharmaceuticals, Inc. | 82.3 Million USD | 100.0% |
Actinium Pharmaceuticals, Inc. | 1.57 Million USD | 100.0% |
Azitra, Inc. | 563.69 Thousand USD | 100.0% |
Can-Fite BioPharma Ltd. | 13 Thousand USD | 100.0% |
Chromocell Therapeutics Corporation | - USD | NaN% |
Calidi Biotherapeutics, Inc. | 2.06 Million USD | 100.0% |
CEL-SCI Corporation | 11.6 Million USD | 100.0% |
iBio, Inc. | 3.5 Million USD | 100.0% |
Lineage Cell Therapeutics, Inc. | 2.07 Million USD | 100.0% |
Matinas BioPharma Holdings, Inc. | 2.89 Million USD | 100.0% |
Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | 100.0% |
NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | 100.0% |
NanoViricides, Inc. | - USD | NaN% |
Oragenics, Inc. | - USD | NaN% |
BiomX Inc. | 5.4 Million USD | 100.0% |
BiomX Inc. | 5.4 Million USD | 100.0% |
Protalix BioTherapeutics, Inc. | 4.62 Million USD | 100.0% |
Palatin Technologies, Inc. | 163.78 Thousand USD | 100.0% |
Scorpius Holdings, Inc. | 12.61 Million USD | 100.0% |